Cargando…
Elevated Levels of the Complement Activation Product C4d in Bronchial Fluids for the Diagnosis of Lung Cancer
Molecular markers in bronchial fluids may contribute to the diagnosis of lung cancer. We previously observed a significant increase of C4d-containing complement degradation fragments in bronchoalveolar lavage (BAL) supernatants from lung cancer patients in a cohort of 50 cases and 22 controls (CUN c...
Autores principales: | Ajona, Daniel, Razquin, Cristina, Pastor, Maria Dolores, Pajares, Maria Jose, Garcia, Javier, Cardenal, Felipe, Fleischhacker, Michael, Lozano, Maria Dolores, Zulueta, Javier J., Schmidt, Bernd, Nadal, Ernest, Paz-Ares, Luis, Montuenga, Luis M., Pio, Ruben |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4370816/ https://www.ncbi.nlm.nih.gov/pubmed/25799154 http://dx.doi.org/10.1371/journal.pone.0119878 |
Ejemplares similares
-
Complement C4d-specific antibodies for the diagnosis of lung cancer
por: Ajona, Daniel, et al.
Publicado: (2017) -
Molecular biomarkers in early stage lung cancer
por: Rodríguez, María, et al.
Publicado: (2021) -
A model based on the quantification of complement C4c, CYFRA 21–1 and CRP exhibits high specificity for the early diagnosis of lung cancer
por: AJONA, DANIEL, et al.
Publicado: (2021) -
Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype
por: Larrayoz, Marta, et al.
Publicado: (2014) -
Complement activation mediates cetuximab inhibition of non-small cell lung cancer tumor growth in vivo
por: Hsu, Yi-Fan, et al.
Publicado: (2010)